SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-23-042389
Filing Date
2023-08-14
Accepted
2023-08-14 16:07:30
Documents
66
Period of Report
2023-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q ikt-20230630.htm   iXBRL 10-Q 1986665
2 EX-31.1 ikt-ex31_1.htm EX-31.1 16982
3 EX-31.2 ikt-ex31_2.htm EX-31.2 17001
4 EX-32.1 ikt-ex32_1.htm EX-32.1 14226
5 EX-32.2 ikt-ex32_2.htm EX-32.2 14226
  Complete submission text file 0000950170-23-042389.txt   6834232

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT ikt-20230630_def.xml EX-101.DEF 151801
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT ikt-20230630_lab.xml EX-101.LAB 361668
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT ikt-20230630_cal.xml EX-101.CAL 34358
9 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT ikt-20230630.xsd EX-101.SCH 46453
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT ikt-20230630_pre.xml EX-101.PRE 274769
60 EXTRACTED XBRL INSTANCE DOCUMENT ikt-20230630_htm.xml XML 1168990
Mailing Address 3350 RIVERWOOD PARKWAY SE, SUITE 1900 ATLANTA GA 30339
Business Address 3350 RIVERWOOD PARKWAY SE, SUITE 1900 ATLANTA GA 30339 678-392-3419
Inhibikase Therapeutics, Inc. (Filer) CIK: 0001750149 (see all company filings)

IRS No.: 263407249 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39676 | Film No.: 231169984
SIC: 2836 Biological Products, (No Diagnostic Substances)